Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
The current standard of care for these patients is to follow and check blood test, though there is no evidence to suggest this is the best practice, Landgren says.
In his presentation at the 17th International Congress on Hematologic Malignancies, Landgren gave an overview of the landscape regard other options in this disease type: ongoing studies, imaging, and molecular profiling studies.
Landgren believes that there will soon be a change in the standard of care, though it is not time to start treating patients outside of clinical trials.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More